BMS Cell Therapy Washington ($BMY)

Overview

Develops, manufactures, and commercializes cancer immunology and cell therapies for people with difficult-to-treat cancers and other serious diseases with unmet medical needs.

Part of the Seattle ecosystem

Related

• Adaptive Biotechnologies ($ADPT)Develops immune-system-based diagnostics and data tools, including NGS MRD testing, for clinicians and biopharma in clinical practice, drug trials, and medicine development.
• Allen Institute for Brain ScienceBuilds brain cell atlases, connectome maps, and analysis platforms to help researchers study mammalian brain organization across development, evolution, disease, and regions.
• ARCH Venture PartnersBuilds and backs science-based companies, investing flexibly in portfolio businesses founded around technologies intended to affect human health and disease.
• Fred Hutchinson Cancer CenterProvides cancer patient care, scientific research, education and training, plus giving and fundraising support for patients, caregivers, clinicians, researchers, and donors.
• Institute for Systems BiologyConducts systems biology research on cancer, health, infectious disease, chronic illness, and environment, while providing education, publications, open-source software, and proteomics services.
• Lumen BioscienceDevelops biologic drugs using spirulina algae to make and deliver therapeutic proteins, addressing scalability and cost barriers in biologic drug development.
• Nautilus Biotechnology ($NAUT)Develops a proteomics platform using Iterative Mapping to quantify proteins and proteoforms, helping researchers study proteome complexity and generate biological insights.
• Sana Biotechnology ($SANA)Builds engineered cell medicines that repair or control genes, or replace damaged cells, for patients with diseases including diabetes, B-cell cancers, and autoimmune disorders.
• TassoBuilds home diagnostic blood collection devices that help patients and clinicians support virtual care, frequent monitoring, and more informed healthcare decisions without traditional needle draws.
• Umoja BiopharmaDevelops in vivo CAR T cell therapies and lentiviral manufacturing to support on-demand treatment, aiming to reduce ex vivo manufacturing delays for patients.
• Variant BioDevelops precision medicines using genomic data from people with exceptional health traits to identify genetically supported targets for inflammation, fibrosis, muscle disorders, and high-unmet-need diseases.
• XanfabBuilds mission-critical circuit card assemblies, PCB assemblies, precision lead-formed components, and electro-mechanical products for aviation, space, and defense manufacturing needs.